Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood progenitor cells (PBPC) have successfully been used as stem cells for both autologous and allogeneic transplants. However, little is known concerning the absolute number and phenotype of primitive progenitors, such as long-term culture-initiating cells (LTC-IC) in mobilized PBPC. The aim of our study was t o evaluate the capacity of G-CSF t o mobilize LTC-IC in the PB of normal individuals and t o evaluate the phenotypic and functional characteristics of G-CSF mobilized LTC-IC. G-CSF was administered t o 29 healthy volunteers at 7.5 p g or 10 pglkgld subcutaneously (SC) for 5 consecutive days and PBPC were harvested on day 6. Mobilization with G-CSF increased the absolute number of week 5 LTC-IC in PB 60-fold, while the number of CD34+ cells and committed colony forming cells (CFC) was increased sevenfold t o 12-fold. The frequency of CFC and week 5 LTC-IC in CD34' cells selected by fluorescence-activated cell sorter (FACS) from mobilized PBPC was 2 & 0.3-fold and 9 f 2.2-fold higher respectively than in CD34+ cells selected from unmobilized PBMNC. CFC were enriched in the CD34+ CD38' and CD34+ HLA-DR' populations. The absolute number of LTC-IC present in CD34' CD38-and CD34+ HLA-DR-cells selected by FACS from either mobilized PBPC, unmobilized PBMNC or steady state bone marrow (BM) was similar (0.5% ARLY MURINE and human studies demonstrating that transfusion of peripheral blood (PB) was capable of protecting recipients from lethal doses of radiation suggested that hematopoietic stem cells may be present in peripheral blood mononuclear cells (PBMNC).'.' Since then, a large number of studies have demonstrated the presence of CD34' cells and committed colony forming cells (CFC) in PBMNC.3" As in vitro assays for stem cells do not exist, less is known concerning the number of stem cells present in PBMNC. Long-term culture-initiating cells (LTC-IC) represent very primitive progenitors capable of initiating and sustaining hematopoiesis for at least 5 weeks in long-term culture6 (LTC) and may serve to approximate the presence of hematopoietic stem cells. The presence of LTC-IC has been demonstrated in steady state PBMNC from normal donors and from patients with hematological malignancie~."~~ Supported by these experimental and initial clinical results, peripheral blood progenitor cells (PBPC) have been increasingly used as a source of stem cells for autologous transplantation".l' and more recently for allogeneic trans-
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The yield of PBPC can be greatly enhanced by using growth factors, such as granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage (GM)-CSF, interleukin (1L)-3, or stem cell factor (SCF), either alone or in combination, chemotherapy or Growth factors alone, chemotherapy alone, or a combination of both increase the relative frequency of CD34+ cells in PBPC by fivefold to 10-fold and the content of CFC.'9+20 As for steady state PBMNC, less is known on the effect of growth factors andor chemotherapy on the mobilization of more primitive progenitors such as LTC-IC. 21 The aim of our study was to evaluate the capacity of G-CSF to mobilize primitive progenitors into the blood of normal donors and further characterize these progenitors. We administered G-CSF to normal individuals and determined the number of LTC-IC mobilized in the blood. We demonstrate that G-CSF mobilizes LTC-IC to a greater extent than CD34' cells or committed CFC. CD34+ CD38-and CD34+ HLA-DR-cells selected from G-CSF mobilized normal PBPC contain similar numbers of primitive progenitors capable of sustaining hematopoiesis in LTC for both 5 and 8 weeks as CD34' CD38-and CD34+ HLA-DR-cells present in steady state PBMNC or bone marrow (BM). However, a large number of progenitors at an intermediate stage of
Evuluution of Samples
The blood and PBPC hematocrit, red blood cell (RBC) count, WBC count, and platelet count were determined using an automated cell counter (S + IV, Coulter Electronics Inc, Hialeah, FL). Flow cytometry, clonogenic assays, and LTC were performed on steady state PBMNC, mobilized PBPC, and steady state bone marrow samples.
Immunophenoryping. Enumeration of CD34' cells in PBMNC or mobilized PBPC samples was performed as described by Sutherland et al.'' In short, PBMNC or mobilized PBPC were stained simultaneously with a fluorescein isothiocyanate (F1TC)-conjugated CD45 antibody (HLe-I; Becton Dickinson, Mountain View, CA) and a phycoerythrin (PE)-conjugated CD34 antibody (HPCA-2-PE). The incidence of true CD34' cells was determined by gating cells for low-density CD45 expression and low-side scatter characteristics.
Cell selection. Steady state PBMNC and BM, but not the leukapheresis products, were separated by Ficoll Hypaque centrifugation (specific gravity, 1077; Sigma Chemical CO, St Louis, MO). CD34 enrichment was done using the MACS CD34 Isolation Kit (Miltenyi Biotec Inc. Sunnyvale, CA) according to the manufacturer's instructions with modifications. Briefly, the PBMNC, mobilized PBPC, or BMMNC cell pellet was resuspended in cold phosphatebuffered saline (PBS) and 0.3% bovine serum albumin (BSA) and incubated with modified CD34 antibody (QBENDIIO, mouse IgGI) for 15 minutes at 4°C and then washed and incubated for 15 minutes with superparamagnetic MACS microbeads recognizing anti-CD34 antibodies. Concurrently, the separation column was flushed with cold PBS and positioned in the MACS magnetic field. The cell suspension was loaded onto the top of the separation column and nonadherent cells were collected. The CD34' cells, which were retained in the column, were then recovered by removing the column from the magnetic field and flushing with buffer. The magnetic separation step was repeated once to obtain a CD34' cell purity over 90% in every sample.
Fluorescence-activated cell sorting (FACS). For FACS selection, CD34 enriched cells were labeled with PE-conjugated mouse anti-CD38, FITC-conjugated mouse anti-HLA-DR (Becton Dickinson), and mouse anti-CD34 conjugated to biotin (Cellpro Inc, Bothell, WA), incubated for 30 minutes on ice then washed with cold PBS and incubated with Streptavidin-REDSA670 (GIBCO-BRL, Grand Island, NY). Cells were selected on a FACStar-Plus laser flow cytometry system equipped with a CONSORT 32 computer for low forward and side scatter properties and expression of CD34, CD38, and HLA-DR antigens using mouse IgGI-PE and IgG2-FITC antibodies and SA670 as control.
Short-term methylcellulose progenitor culture. Cells were cultured at 2 X 10' cells/mL (for the different CD34 subpopulations) or 2 X 10' cells/mL (for unselected MNC) in methylcellulose containing Iscove's modified Dulbecco's medium (IMDM; GIBCO Laboratories, Grand Island, NY), supplemented with 30% fetal calf serum (FCS; Hyclone, Logan, UT), 3 IU erythropoietin (Epoietin; Amgen, Thousand Oaks, CA) and 10% 5637 bladder carcinomaconditioned media as described.2h Cultures were incubated in a humidified atmosphere at 37°C and 5%
CO2. The cultures were assessed at day 14 to 18 for the presence of burst-forming unit erythroid (BFU-E), colony-forming unit granulocyte-macrophage (CFU-GM). and CFU-Mix as previously described."
LTC
Complete long-term culture medium. LTC medium consisted of IMDM with 12.5% FCS, 12.5% horse serum (Terry Fox Laboratories, Vancouver, Canada), 2 mmol/L glutamine (GIBCO), penicillin 100 U/mL, streptomycin 100 U/mL (GIBCO) and IO-' hydrocortisone.*' Stromal feeders. M2-10B4 cells, a generous gift from Dr C. Eaves (Vancouver, British Columbia, Canada), were maintained in RPM1 (GIBCO Laboratories) + 10% fetal calf serum. We and others have shown that these murine marrow stroma-derived fibroblasts can support human hematopoiesis in stroma-contact and stromanoncontact cultures to the same extent as normal human marrow stromal feeder^.^"^^ M2-10B4 cells were subcultured in wells of 6-well or 96-well plates. Once confluent, plates were irradiated with 6,000 cGy and the medium was changed to LTC medium.
LTC. LTC were established by plating 5 X l@ mobilized PBPC or 5,000 FACS selected CD34' subpopulations in direct contact with normal M2-10B4 stromal layers subcultured in 6-well plates. Cultures were maintained for 5 weeks in a humidified atmosphere, at 37°C and 5% COz. Weekly media changes were performed by removing half the cell free supernatant medium and replacing it with fresh LTC medium. To determine the number of CFC present in LTC, cells were harvested by digesting the stromal layers with trypsin and replated in methylcellulose progenitor culture.
Enumeration of LTC-IC by limiting dilution assays (LDA). TWO million PBMNC (22 replicates: 61,224; 20,408; 6,802; 2,267 cells/ well) and 10,OOO cells from CD34' subpopulations (22 replicates: 300, 100, 33, 11 cellslwell) were plated in limiting dilutions onto previously irradiated M2-10B4 feeders. Cultures were maintained in a humidified atmosphere, at 37°C and 5% CO,. Weekly, half of the medium was replaced by fresh LTC medium. After 5 weeks, unless
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RESULTS

Mobilization of Committed Progenitors and LTC-IC With G-CSF
Twenty-nine normal donors were included in the study. Fifteen subjects received 10 pgkg G-CSF sc for 5 days, while 14 subjects received 7.5 pgkg for 5 days. Since the number of W C , CD34+ cells, BFU-E, CFU-GM, CFU-Mix or LTC-IC mobilized in PBPC following administration of either 7.5 pgkg or 10 pgkg of G-CSF was not statistically different, analyses were done using results obtained from all 29 individuals.
Administration of G-CSF increased the total number o f WBC sevenfold, the percentage of CD34+ cells eightfold, and the number of BFU-E, CFU-GM, and CFU-Mix per 100,OOO MNC sevenfold, ninefold, and 12-fold respectively over baseline ( Table 1) . In contrast, the absolute number of LTC-IC in G-CSF mobilized PBPC increased 59-fold over that in unmobilized PBMNC ( Table 1 ). The fold increase in 2035 LTC-IC was significantly higher than the increase in BFU-E (P < .Ol), CFU-GM ( P < .008), CFU-Mix ( P < .Ol), and CD34+ cells ( P < .01). Interestingly, the number of secondary CFC generated per LTC-IC present in G-CSF mobilized PBPC after 5 weeks in LTC in four different experiments was only 1.3 k 0.3 CFCLTC-IC (defined as the total number of CFC in LTC initiated with mobilized PBPC divided by the absolute number of LTC-IC determined by LDA in that population). This is significantly lower than the number of CFC per LTC-IC present in steady state BM or PBMNC733'332 which ranges between 4 and 6 CFC per Both the number of CFU-GM and CD34+ cells have been used as predictors for early engraftment after transplantathan committed, progenitors may be responsible for early recovery of hematopoiesis after tran~plantation,~~'~~ we ex- The mean volume of the G-CSF mobilized PBPC product obtained from a single leukapheresis was 371 ? 15 mL containing 92.6 5 4.8 X IO6 WBC/mL. The total number of CD34+ cells obtained varied between 91.3 and 1758 X lo6 or 1.2 X 106kg to 23 X lo6 kg for a 75-kg recipient. The total dose of CFU-GM varied between 17.1 X lo6 and 150 X lo6 or 1.78 X 105/kg and 20 X 105kg for a 75-kg recipient (Table 2 ). In 21 of 26 (80.7%) donors, more than 2 X lo6 CD34' cellskg for a 75-kg patient were obtained. The number of CFU-GM per kg for a 75-kg patient was higher than 2 X lo5 in 25 of 26 (96%) donors.
G-CSF Significantly Increases Myeloid Progenitors Within the CD34' Cells
LTC-IC.
tion.33,'4 Because recent studies suggest that primitive, rather FACS selected CD34+ cells (purity >99.2%) were evaluated for their content of CFC and LTC-IC before and after mobilization with G-CSF. There was a statistically significant increase in the clonogenic capacity for both the committed progenitors (BFU-E: 1.79-fold, P < .02; CFU-GM: 2.5-fold, P < .02; CFU-Mix: 2.54-fold, P < .02) (Fig 1A through  C) and for the more primitive LTC-IC (ninefold, P < .01) after mobilization with G-CSF (Fig ID) . The fraction of identifiable progenitors (equal to the percentage of cells that gave rise to CFU-GM, BFU-E, and CFU-Mix + the percentage of cells that could initiate LTC) in the unmobilized CD34' cells was 13.9% 2 2. 1%. After mobilization with G-CSF the percentage of identifiable progenitors present in FACS selected CD34' cells increased to 28.7% ? 2.13% ( P < .01) (Fig 2) .
LTC-IC Can Be Found in the CD34' CD38' or CD34' CD38-and CD34' HLA-DR' or CD34' HLA-DRFraction of G-CSF Mobilized PBPC
We next analyzed the phenotype of CD34' cells before and after mobilization with G-CSF. There were no statistically significant differences between the percentage of CD34' cells that expressed CD38 before and after mobilization. However, the percentage of CD34* cells expressing the HLA-DR antigen increased from 82.3% +-2% in steady state PBMNC to 89.9% 2 1% in PBPC obtained after G-CSF mobilization ( P = .002) ( Table 3) . Mobilized PBPC were then sorted based on CD38 and HLA-DR antigen expression into CD34' CD38', CD34' CD38-, CD34' HLA-DR', CD34' HLA-DR-cells, all with a purity over 99.5%. clonogenic progenitors were highly enriched in the CD34' CD38' and to a lesser extent in the CD34' HLA-DR' fraction of G-CSF mobilized PBPC (Table 4 ). The absolute number of LTC-IC per 1 0 0 sorted cells, determined by LDA, in G-CSF mobilized PBPC CD34' CD38-cells was similar to that seen in steady state BM-derived CD34' CD38-( Fig  4A and B) or unmobilized PBMNC CD34' CD38-cells (data not shown). Likewise, the frequency of LTC-IC in CD34' HLA-DR-cells from BM and mobilized PBPC was equivalent (0.4% 2 0.1% L'rC-IC in mobilized PBPC CD34' HLA-DR-cells, n = 4 and 0.68% +-0.16% LTC-IC in BM CD34' HLA-DR. cells, n = 4). Surprisingly, 2.5% t-0.9% mobilized CD34' CD38' cells and 0.98% +-0.2% mobilized CD34' HLA-DR' cells were capable of initiating and sustaining hematopoiesis in stromal cultures for 5 weeks. This is significantly higher than what was observed for CD34' CD38-and CD34.' HLA-DR-subpopulations from mobilized PBPC ( P < . O l ) or that of CD34' CD38' and CD38-or CD34' HLA-DR' and HLA-DRcells present in steady state BM ( P < .05) (Fig 4A and B) .
CD34' CD38' and CD34' HLA-DR' LTC-IC Present in Mobilized PBPC Are More Mature Than CD34' CD38-and CD34' HLA-DR-LTC-IC
The definition of an LTC-IC is "a cell capable of initiating and sustaining long-term cultures for at least 5 weeks". However, we" and others" have demonstrated that LTC-IC still represent a spectrum of progenitors. Some progenitors are capable of sustaining hematopoiesis for S weeks, but not longer, while possibly less mature LTC-IC can sustain hematopoiesis for 8 or more weeks. To further examine the maturation stage of LTC-IC present in G-CSF mobilized CD34' subpopulations, we performed additional experiments in which the LTC were maintained for 8 weeks. Threefold less cells present in mobilized CD34' CD38-cells were able to initiate and sustain hematopoiesis in LTC for 8 weeks compared with 5 weeks. However, 20-fold less cells present in the CD34' CD38' fraction of mobilized PBPC were capable of suspaining hematopoiesis for 8 weeks (Fig 4 8 and C) . Likewise, fourfold less mobilized CD34' HLA-DR-cells sustained hematopoiesis for 8 compared with S weeks (0.68% ? 0.16% at S weeks versus 0.15% t 0.02% at 8 weeks; P = .09, n = 4). but IO-fold less mobilized CD34' HLA-DR' cells sustained hematopoiesis for 8 rather than 5 weeks (1% ? 0.2% at S weeks versus 0.13% ? 0.04% at 8 weeks; P = .01, n = 4). Thus, when LTC were maintained for 8 weeks, the phenotype of LTC-IC was CD34' CD38-and CD34' HLA-DR-and no longer CD34' CD38' and CD34' HLA-DR+. Consistent with the notion that CD34' CD38' and CD34' HLA-DR' LTC-IC are more mature than CD34' CD38-and CD34' HLA-DR-LTC-IC is our observation that the number of CFC generated per LTC-IC from CD34' CD38' and CD34' HLA-DR' populations was only 2.6 ? 0.27 (n = 5), which was significantly lower than the number of CFC generated per CD34' CD38 and CD34' HLA-DR-LTC-IC (13.2 t 2.5, n = 5) ( P < .01).
DISCUSSION
In this study, we demonstrate that G-CSF increases the absolute number of week S LTC-IC 59-fold in MNC of peripheral blood of normal healthy donors, which is significantly higher than the mobilization of either phenotypically defined CD34' progenitors or functionally defined CFU-GM or CFC. Previous studies have documented the presence of LTC-IC in mobilized PBPC from patients with malignancies.'." Henschler et al" showed that the frequency of LTC-IC in unseparated mobilized PBPC was 1:9,075 cells, while Pettengell et alx found a frequency of LTC-IC in mobilized PBPC of 1:10,302. In our study, we demonstrate that the frequency of LTC-IC in G-CSF mobilized PBPC from normal donors is 1:6,000. The higher frequency of LTC-IC mobilized in PBPC from normal donors compared with patients with malignancies may be due to the fact that patients, but not normal donors, have previously been treated with chemotherapy. CFC and LTC-IC in steady state PB were enumerated in MNC obtained after Ficoll-Hypaque separation, while CFC and LTC-IC in mobilized PBPC were enumerated in the apheresis product without further processing. Although density centrifugation and the apheresis process may alter the proportion of different populations present in the MNC fraction, we do not believe that differences in CFC and LTC-IC frequencies can be attributed solely to differences in MNC preparation techniques.
Infusion of a minimum of 2 X IO" CD34' cells per kg is required for timely multilineage engraftment after autologous transplantation and infusion of more than 5 X 10" CD34' cellskg has been associated with early trilineage engraftment after autologous tran~plantation.~' Likewise, transplantation with more than S X 10" CD34' cells present in allogeneic PBPC results in engraftment between day 9 and day 25."." We demonstrate here that administration of 7.5 pgkglday of G-CSF for S days followed by a single 3-hour leukapheresis provided more that 2 X IO" CD34' per kg for a 75-kg recipient in more than 80% of the donors and more than 5 X lo6 CD34' cells per kg in 16 of 26 donors (61 %). However, the number of CD34' cells recovered from different G-CSF-treated normal individuals varied significantly. This is in accordance with recent reportsgK demonstrating that the number of progenitors in PBPC varies not only between patients and normals, but also between different normal donors. Increasing the duration of the leukapheresis may be one way to increase the likelihood of obtaining sufficient CD34' cells for transplant in a single leukapheresis from the majority of normal donors. frequency of either CFU-GM or LTC-IC, which may be due to the inaccuracy in determining the very low percent of CD34' cells present in unmobilized PBMNC. Although the frequency of CD34' cells in G-CSF mobilized PBPC was predictive of the CFU-GM frequency, neither CD34' cells nor CFU-GM frequency in mobilized PBPC correlated with the frequency of LTC-IC. Clinical studies will need to demonstrate whether LTC-IC rather than CFU-GM or CFC predict early engraftment.
CD34' cells comprise a heterogeneous population including committed myeloid and lymphoid progenitors and also more primitive progenitors and stem cells. Differences in the relative frequency of these subpopulations underlie the populations may represent a more mature progenitor. Further evidence that CD34' CD38' and CD34' HLA-DR' progenitors capable of sustaining hematopoiesis for 5 weeks may represent a more mature progenitor than CD34' CD38-and CD34' HLA-DR-LTC-IC comes from our own studies and studies from Sutherland et al" which demonstrate that the number of secondary CFC per LTC-IC in mobilized PBMNC is only 1 to 1.5, which is significantly lower than that of steady state BM or PBMNC (4 to 6 CFC per LTC-IC). Since more than 85% of mobilized These results indicate also that the overall increase in LTC-IC frequency in mobilized PBPC as shown in Table 1 is an overestimation, since this is based on week 5 cultures, representing CD34' CD38' as well as more primitive CD34' CD38-LTC-IC. The increase in CD34' CD38-cells, containing primitive LTC-IC that can sustain hematopoiesis for more than 5 weeks is only sixfold to eightfold in the mobilized PBPC population compared with steady state blood. Further, only 15% of CD34' cells are CD34' CD38-indicating that the true increase in primitive LTC-IC that can sustain hematopoiesis for more than 5 weeks is only 5.1-fold (15% of 60-fold). It is thus, imperative to use the term LTC-IC with care when assessing mobilized PBPC collections, since 85% of progenitors that read out at 5 weeks in LTC cannot sustain hematopoiesis beyond 5 weeks and have decreased proliferative potential. These findings also have implications for the evaluation of ex vivo stem cell expansion cultures. Comparison of week 8 LTC-IC in uncultured and cultured products will be required to demonstrate ex vivo expansion of the more primitive progenitor pool.
In conclusion, we demonstrate that G-CSF mobilizes week 
